Expensive brain-cancer drug no longer an option under Medicare cbsnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cbsnews.com Daily Mail and Mail on Sunday newspapers.
The National Foundation for Cancer Research (NFCR) announced winners of the 2021 Salisbury Award Competition for Entrepreneurial Translational Research, selected from among eight semi-finalists after pitch presentations in front of a judging committee consisting of prominent cancer research scientists, clinicians, early-stage investors and business leaders.
Credit: National Foundation for Cancer Research, RadioMedix, TanoMed, Tel Aviv University, Libera Bio
ROCKVILLE, MD - The National Foundation for Cancer Research (NFCR) announced winners of the 2021 Salisbury Award Competition for Entrepreneurial Translational Research, selected from among eight semi-finalists after pitch presentations in front of a judging committee consisting of prominent cancer research scientists, clinicians, early-stage investors and business leaders.
The semi-finalists were determined earlier in the spring based upon applications from among academic laboratories or early-stage companies advancing promising experimental cancer therapeutic, diagnostic, detection and vaccine innovations.
The first prize winner of the Salisbury Award Competition is the cancer therapeutic innovation presented by Ronit Satchi-Fainaro, Ph.D., co-founder and chief scientific officer (CSO) of Israel-based TanoMed, and a professor at Tel Aviv University and director of its Cancer Bio
E-Mail
DURHAM, N.C. - Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they ve grown back, enabling up to 20% of patients to live well beyond predicted survival times.
What causes this effect has long been the pursuit of researchers hoping to harness immunotherapies to extend more lives.
New insights from a team led by Duke s Preston Robert Tisch Brain Tumor Center provide potential answers. The team found that recurring glioblastoma tumors with very few mutations are far more vulnerable to immunotherapies than similar tumors with an abundance of mutations.
The finding, appearing online Jan. 13 in the journal